Core Viewpoint - Zhonghui Biotech-B (02627) has received approval from the National Medical Products Administration of China for its quadrivalent influenza virus subunit vaccine, making it the first and only approved vaccine for all age groups in China [1][2]. Group 1: Company Developments - Zhonghui Biotech-B's stock rose over 8%, currently trading at 51.25 HKD with a transaction volume of 18.463 million HKD [1]. - The quadrivalent influenza virus subunit vaccine is a significant upgrade from traditional split virus vaccines, offering comprehensive protection, high purity of antigen components, and lower risk of adverse reactions [1][2]. Group 2: Market Position - The newly approved vaccine is the only vaccine product included in the preliminary review list for innovative drugs under commercial insurance, highlighting its rarity and potential to fill a market gap [1]. - The vaccine utilizes a third-generation technology route, optimizing production processes to extract effective antigen components, which enhances safety, immune response, and overall quality compared to second-generation split vaccines [2].
港股异动 | 中慧生物-B(02627)涨超8% 四价流感病毒亚单位疫苗入选商保初步审查名单 市场稀缺性显著